Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 30, 2015
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for an extended...
- Nov 18, 2015Clinical Study (MORAb-009-201) of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma (MPM)
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in the randomized, double-blind ARTEMIS—Amatuximab Research in Treatment-naïve Epithelial...
- Nov 17, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into an agreement with the Targeted Alpha Therapy Group (TAT Group) at the University of Gothenburg in Sweden to...
-
Nov 13, 2015
Helsinn Group and Eisai Inc. announced today that the American Society of Clinical Oncology (ASCO) has published a focused update to its clinical practice guidelines for antiemetics in oncology...
- Nov 9, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of Seattle, WA, a privately held biotechnology company...
-
Nov 4, 2015The parties hope to develop new cancer targets and novel therapeutic approaches
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has initiated a research collaboration for research and development with the Paoli Calmettes Institute (IPC),...
- Oct 26, 2015
Eisai Inc. announced today that Halaven® (eribulin mesylate) Injection has been nominated by the Galien Foundation within the category, "Best Pharmaceutical Agent of the Year" at the ninth annual...
- Oct 26, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive effects of the CA125 tumor antigen on the investigational...
-
Oct 19, 2015Findings suggest need for improved dialogue between patients receiving chemotherapy and their healthcare team, including pharmacists
-
Oct 16, 2015
Results from an investigational Phase 2 clinical trial evaluating lenvatinib in combination with everolimus and lenvatinib and everolimus alone for the treatment of metastatic renal cell carcinoma...
